Information Provided By: 
Fly News Breaks for September 27, 2016
WST
Sep 27, 2016 | 09:02 EDT
Janney Capital analyst Paul Knight noted that shares of West Pharmaceutical have slid about 10% in the last few weeks, which he attributes to the company's gross margin guidance and a competitor downgrade, but he recommends buying the stock on the weakness. The analyst, who sees a multi-year growth cycle on the horizon for West as new biologic therapies are approved, thinks the company's 6-8% revenue growth guidance is conservative and keeps a Buy rating and $90 fair value estimate on the shares.
News For WST From the Last 2 Days
There are no results for your query WST
